QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roberts, F. Articles by Ryan, G. J Search for Related Content PubMed PubMed Citation Articles by Roberts, F. Articles by Ryan, G. J

DRUG INFORMATION ROUNDS

The Safety of Metformin in Heart Failure

PharmD Student, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA

Gina J Ryan, PharmD BCPS CDE

Clinical Assistant Professor, College of Pharmacy and Health Sciences, Mercer University

Reprints: Dr. Ryan, Department of Clinical and Administrative Sciences, College of Pharmacy and Health Sciences, Mercer University, 3001 Mercer University Dr., Atlanta, GA 30341, fax 678/547-6384, ryan_gi{at}mercer.edu

OBJECTIVE: To examine the evidence regarding the safety of metformin in heart failure.

DATA SOURCES: Searches in MEDLINE and International Pharmaceutical Abstracts were performed (1966–February 2007). Search terms included metformin, heart failure, lactic acidosis, clinical trials, and insulin resistance.

STUDY SELECTION AND DATA EXTRACTION: Published studies and case reports that evaluated the causal link between metformin and lactic acidosis in patients with heart failure were selected for review.

DATA SYNTHESIS: There were no case reports of patients who had metformin-associated lactic acidosis when heart failure was the only contraindication. Two large retrospective studies showed that metformin does not increase the risk of lactic acidosis in patients with heart failure. However, these retrospective analyses did not account for many important confounding variables. A reduction in mortality rates in metformin users with New York Heart Association Class III and IV heart failure was observed in one small (N = 94) prospective trial.

CONCLUSIONS: Results from 3 trials suggest that metformin may be safe to use in heart failure. Large prospective trials are needed to provide conclusive evidence regarding metformin's safety. Until then, use of metformin in heart failure patients should not be recommended routinely. If it is used in patients with heart failure, they should be monitored closely for signs of lactic acidosis.

Key Words: heart failure, lactic acidosis, metformin

Published Online, March 20, 2007. www.theannals.com, DOI 10.1345/aph.1H523

This article has been cited by other articles:

				S. Gundewar, J. W. Calvert, S. Jha, I. Toedt-Pingel, S. Yong Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian, and D. J. Lefer Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure Circ. Res., February 13, 2009; 104(3): 403 - 411. [Abstract] [Full Text] [PDF]

				N. F Wiernsperger Review: 50 years later: is metformin a vascular drug with antidiabetic properties? The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 204 - 210. [Abstract] [PDF]